Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurobiological Technologies, a biopharmaceutical company, has received a quarterly royalty payment of approximately $1.5 million from Merz Pharmaceuticals, a developer of therapies for central nervous system and liver metabolism, for sales of Memantine for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
Under an exclusive marketing agreement, Neurobiological Technologies (NTI) currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners.